Press Room

AAPS 2025 PharmSci 360

Start
Sunday, November 09, 2025
End
Wednesday, November 12, 2025
Location: San Antonio, TX, United States
Booth Number: 2943

Hovione is exhibiting at the AAPS 2025 PHarmSCi 360, a convener of the pharmaceutical science community, bringing together thousands of scientists from across the world. PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a small niche meeting because of its unique programming structure built on five tracks that cover the pharmaceutical development process. 

On November 10th, 9:00 AM to 9:30 AM, our expert Sarang Oka, Fellow Scientist - Technology Intensification, will lead the Session: 

Addressing Practical Challenges in CM via Novel Hardware and Automation

This work tackles critical operational challenges in continuous manufacturing processes for oral drug products, focusing on scalability, automation, and efficiency. Key issues include the complexity and manual nature of residence time distribution (RTD) experiments, non-automated execution of multi-point design of experiments (DOEs), and throughput limitations tied to existing continuous manufacturing equipment for oral solids. Innovative hardware and automation-based solutions have been developed to address the aforementioned challenges.

Key learnings of the session:

  • Participants will learn of automated, novel approaches to execute residence time distribution experiments in CM process trains.
  • Participants will learn of automated, novel approaches to execute DOEs in CM process trains, coupled with automated sampling with the goal of one-person DOE execution.
  • Participants will learn of a novel approach that combines batch and continuous processing in a single process train and how built-in modularity enables the operation over a wide throughput range.

Meet the Hovione team at booth # 2943

This is the perfect opportunity to speak with our experts and learn how a Specialist Integrated CDMO can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.

Schedule a meeting today.

schedule a meeting

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025